<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220223054108N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-04-03</date_registration>
      <primary_sponsor>Gorgan University of Medical Sciences</primary_sponsor>
      <public_title>Effects of nanocurcumin and chlorhexidine mouthwash on levels of interleukin 1 and 6</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of nanocurcumin and chlorhexidine mouthwash on levels of gingival crevicular fluid interleukin 1 and 6 in patients undergoing fixed orthodontics treatment</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-04-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>88</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62597</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Factorial, Purpose: Prevention, Randomization description: Eligible subjects will be assigned to the nanocurcumin and chlorhexidine mouthwash groups, the nanocurcumin only and chlorhexidine only, and the control group using the random block method. We first create a random sequence of 11 eight-block random blocks. In each block, each letter A, B, C, D is repeated twice.
 ABCDACDB, CADBACBD, DACBBCAD, ABBCDACD, CADBACDB,…
 In the desired sequence, there will be 22 letters from each letter A, B, C, D. According to the above block, 88 envelopes will be prepared, and in each envelope, the letters A, B, C, D will be placed and will be numbered from 1 to 88. The person delivering the envelopes to the patients does not know what is inside. A random sequence is produced by a statistics and methodology consultant who does not have access to patients, and only he knows what is in each number.
 Patients who received the letter A in the nanocurcumin and chlorhexidine mouthwash group, patients who received the letter B in the nanocurcumin group, and patients who received the letter C in the chlorhexidine group patients who received the letter D in the control group will be placed, Blinding description: A random sequence is produced by a statistics and methodology consultant who does not have access to patients, and only he knows what is in each number.</study_design>
      <phase>2-3</phase>
      <hc_freetext>teeth shifting.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: In this group, patients are asked to mix 20 drops of nanocurcumin mouthwash with 10 cc of water and use for 30 seconds as a mouthwash twice a day for two weeks after brushing. Dr. Khori Danesh Bonyan Pharmaceutical Company makes Nanocurcumin mouthwash with a concentration of 2% with confirmation code No. 184620 of Golestan University of Medical Sciences. This mouthwash is prepared with the chemical composition C21H20O6 with over 70% purity degree and a molecular weight of 368 from Sigma &amp; Aldrich Co. Intervention 2: Intervention group 2: In this group, patients are asked to mix 20 drops of 2% chlorhexidine mouthwash  with 10 cc of water and use for 30 seconds  according to the written instruction on the mouthwash twice a day for two weeks after brushing. Intervention 3: Intervention group 3: In this group, patients are asked to mix 20 drops of nano-curcumin plus chlorhexidine combined mouthwash with 10 cc of water and use for 30 seconds as a mouthwash twice a day for two weeks after brushing. Intervention 4: Control group: In this group, patients are asked to use 10 cc of normal saline as a mouthwash for 30 seconds as a mouthwash twice a day for two weeks after brushing.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Aliakbar Naghavialhosseini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahryar 5 St., Shahryar Town</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4913983635</zip>
        <telephone>+98 17 3262 7823</telephone>
        <email>a.a.nagavi@gmail.com</email>
        <affiliation>Gorgan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Aliakbar Naghavialhosseini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahryar 5 St., Shahryar Town</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4913983635</zip>
        <telephone>+98 17 3262 7823</telephone>
        <email>a.a.nagavi@gmail.com</email>
        <affiliation>Gorgan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Agreement to participation in the current study
15 to 35 years old
Good periodontal health
Systemically healthy
Passed at least 2 mounts after fixed orthodontics treatment
Negative for hypersensitivity to Curcumin and/or chlorhexidine.</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>35 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Tobacco usage
Antibiotics, Aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) usage during the past one month
Pregnant and lactating mothers</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: In this group, patients are asked to mix 20 drops of nanocurcumin mouthwash with 10 cc of water and use for 30 seconds as a mouthwash twice a day for two weeks after brushing. Dr. Khori Danesh Bonyan Pharmaceutical Company makes Nanocurcumin mouthwash with a concentration of 2% with confirmation code No. 184620 of Golestan University of Medical Sciences. This mouthwash is prepared with the chemical composition C21H20O6 with over 70% purity degree and a molecular weight of 368 from Sigma &amp; Aldrich Co.</i_keyword>
      <i_keyword>Intervention group 2: In this group, patients are asked to mix 20 drops of 2% chlorhexidine mouthwash  with 10 cc of water and use for 30 seconds  according to the written instruction on the mouthwash twice a day for two weeks after brushing.</i_keyword>
      <i_keyword>Intervention group 3: In this group, patients are asked to mix 20 drops of nano-curcumin plus chlorhexidine combined mouthwash with 10 cc of water and use for 30 seconds as a mouthwash twice a day for two weeks after brushing.</i_keyword>
      <i_keyword>Control group: In this group, patients are asked to use 10 cc of normal saline as a mouthwash for 30 seconds as a mouthwash twice a day for two weeks after brushing.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Interleukin 1 &amp; 6 before and two weeks later in the patients consuming curcumin mouthwash. Timepoint: Measurement of Interleukin1 &amp; 6 in the study baseline (before treatment beginning) and 2 weeks after starting fixed orthodontic treatment. Method of measurement: Enzyme-linked Immunosorbent Assay (ELISA test).</prim_outcome>
      <prim_outcome>Interleukin 1 &amp; 6 before and two weeks later in the group of patients consuming chlorhexidine mouthwash. Timepoint: Measurement of Interleukin 1 &amp; 6 in the study baseline (before treatment beginning) and 2 weeks after starting fixed orthodontic treatment. Method of measurement: Enzyme-linked Immunosorbent Assay (ELISA test).</prim_outcome>
      <prim_outcome>Interleukin 1 &amp; 6 before and two weeks after in the group consuming curcumin + chlorhexidine mouthwash. Timepoint: Measurement of Interleukin 1 &amp; 6 in the study baseline (before treatment beginning) and 2 weeks after starting fixed orthodontic treatment. Method of measurement: Enzyme-linked Immunosorbent Assay (ELISA test).</prim_outcome>
      <prim_outcome>Interleukin 1 &amp; 6 before and two weeks after in the group of patients consuming normal saline mouthwash. Timepoint: Measurement of Interleukin 1 &amp; 6 in the study baseline (before treatment beginning) and 2 weeks after starting fixed orthodontic treatment. Method of measurement: Enzyme-linked Immunosorbent Assay (ELISA test).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Comparison of differences in Interleukin 1 &amp; 6 concentration before and two weeks later between two groups of patients using mouthwash containing curcumin and chlorhexidine. Timepoint: before treatment and 2 weeks after starting fixed orthodontic treatment. Method of measurement: ELISA (enzyme-linked immunosorbent assay).</sec_outcome>
      <sec_outcome>Comparison of difference in Interleukin1 &amp; 6 concentration before and two weeks later between two groups of patients using mouthwash containing curcumin and curcumin + chlorhexidine. Timepoint: before treatment and 2 weeks after starting fixed orthodontic treatment. Method of measurement: ELISA (enzyme-linked immunosorbent assay).</sec_outcome>
      <sec_outcome>Comparison of differences in Interleukin1 &amp; 6 concentration before and 2 weeks later between 2 groups of patients using mouthwash containing curcumin and normal saline. Timepoint: before treatment and 2 weeks after starting fixed orthodontic treatment. Method of measurement: ELISA (enzyme-linked immunosorbent assay).</sec_outcome>
      <sec_outcome>Comparison of differences in Interleukin1 &amp; 6 concentration before and 2 weeks later between 2 groups of patients using mouthwash containing chlorhexidine and curcumin+ chlorhexidine. Timepoint: before treatment and 2 weeks after starting fixed orthodontic treatment. Method of measurement: ELISA (enzyme-linked immunosorbent assay).</sec_outcome>
      <sec_outcome>Comparison of differences in Interleukin1 &amp; 6 concentration before and 2 weeks later between 2 groups of patients using mouthwash containing  chlorhexidine and normal saline. Timepoint: before treatment and 2 weeks after starting fixed orthodontic treatment. Method of measurement: ELISA (enzyme-linked immunosorbent assay).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Gorgan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-01-30</approval_date>
        <contact_name>Research Ethics Committees of Golestan University of Medical Sciences</contact_name>
        <contact_address>Shahryar Gorgan Golestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
